Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Rotrosen

Showing results (71-80 of 157) with videos related to

Pageof 16
Sort By:
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 17, 2021
A neuroeconomic signature of opioid craving: How fluctuations in craving bias drug-related and nondrug-related valueKathryn Biernacki, Silvia Lopez-Guzman, John C Messinger, et al.
Pharmacogenomics|June 9, 2016
African-specific variability in the acetylcholine muscarinic receptor M4: association with cocaine and heroin addictionOrna Levran, Matthew Randesi, Einat Peles, et al.
Pharmacogenomics|December 19, 2014
Dopaminergic pathway polymorphisms and heroin addiction: further support for association of CSNK1E variantsOrna Levran, Einat Peles, Matthew Randesi, et al.
The American Journal of Psychiatry|June 25, 2021
Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of TreatmentEdward V Nunes, Jennifer M Scodes, Martina Pavlicova, et al.
Lancet Regional Health. Americas|December 28, 2023
Retention and critical outcomes among new methadone maintenance patients following extended take-home reforms: a retrospective observational cohort studyArthur Robin Williams, Noa Krawczyk, Mei-Chen Hu, et al.
Pharmacogenomics|February 22, 2018
Genetic variations in genes of the stress response pathway are associated with prolonged abstinence from heroinOrna Levran, Einat Peles, Matthew Randesi, et al.
Alcoholism, Clinical and Experimental Research|October 26, 2021
Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trialJohn D Roache, Martina Pavlicova, Aimee Campbell, et al.
Psychiatric Services (Washington, D.C.)|June 20, 2023
Impact of Medication-Based Treatment on Health Care Utilization Among Individuals With Opioid Use DisorderManesh Gopaldas, Kevin Wenzel, Aimee N C Campbell, et al.
Journal of Substance Abuse Treatment|November 1, 2011
A preliminary study of the effects of individual patient-level feedback in outpatient substance abuse treatment programsPaul Crits-Christoph, Sarah Ring-Kurtz, Jessica L Hamilton, et al.
Journal of Substance Abuse Treatment|May 24, 2006
Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: the National Drug Abuse Treatment Clinical Trials NetworkLawrence S Brown, Steven Allan Kritz, R Jeffrey Goldsmith, et al.
Pageof 16

Showing results (71-80 of 157) with videos related to

Sort By:
Pageof 16
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 17, 2021
A neuroeconomic signature of opioid craving: How fluctuations in craving bias drug-related and nondrug-related valueKathryn Biernacki, Silvia Lopez-Guzman, John C Messinger, et al.
Pharmacogenomics|June 9, 2016
African-specific variability in the acetylcholine muscarinic receptor M4: association with cocaine and heroin addictionOrna Levran, Matthew Randesi, Einat Peles, et al.
Pharmacogenomics|December 19, 2014
Dopaminergic pathway polymorphisms and heroin addiction: further support for association of CSNK1E variantsOrna Levran, Einat Peles, Matthew Randesi, et al.
The American Journal of Psychiatry|June 25, 2021
Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of TreatmentEdward V Nunes, Jennifer M Scodes, Martina Pavlicova, et al.
Lancet Regional Health. Americas|December 28, 2023
Retention and critical outcomes among new methadone maintenance patients following extended take-home reforms: a retrospective observational cohort studyArthur Robin Williams, Noa Krawczyk, Mei-Chen Hu, et al.
Pharmacogenomics|February 22, 2018
Genetic variations in genes of the stress response pathway are associated with prolonged abstinence from heroinOrna Levran, Einat Peles, Matthew Randesi, et al.
Alcoholism, Clinical and Experimental Research|October 26, 2021
Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trialJohn D Roache, Martina Pavlicova, Aimee Campbell, et al.
Psychiatric Services (Washington, D.C.)|June 20, 2023
Impact of Medication-Based Treatment on Health Care Utilization Among Individuals With Opioid Use DisorderManesh Gopaldas, Kevin Wenzel, Aimee N C Campbell, et al.
Journal of Substance Abuse Treatment|November 1, 2011
A preliminary study of the effects of individual patient-level feedback in outpatient substance abuse treatment programsPaul Crits-Christoph, Sarah Ring-Kurtz, Jessica L Hamilton, et al.
Journal of Substance Abuse Treatment|May 24, 2006
Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: the National Drug Abuse Treatment Clinical Trials NetworkLawrence S Brown, Steven Allan Kritz, R Jeffrey Goldsmith, et al.
Pageof 16